<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00224757</url>
  </required_header>
  <id_info>
    <org_study_id>0415</org_study_id>
    <nct_id>NCT00224757</nct_id>
  </id_info>
  <brief_title>Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation - TIARA Pilot Study</brief_title>
  <acronym>TIARA</acronym>
  <official_title>Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Interuniversity Cardiology Institute of the Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Interuniversity Cardiology Institute of the Netherlands</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi centre pilot study we will perform TEE in patients with AF who are eligible for
      VKA treatment. TTE will be used as pre-screening: if TTE shows left atrial abnormalities or
      aortic plaque, patients will be excluded from randomisation. TEE will be performed in all
      other patients to detect or exclude complex aorta plaques or signs of left atrial stasis.
      Three hundred patients who do not have these features on TTE will be randomly assigned to
      treatment with aspirin or VKA. Follow-up will be 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND Atrial fibrillation (AF) is an independent risk factor for stroke. Therapy with
      vitamin K antagonists (VKA) and aspirin reduces the risk of thromboembolism (TE)
      dramatically. Risk stratification is nowadays based on clinical characteristics. However,
      many high risk AF patients may actually be at low risk, identified by trans-oesophageal
      echocardiography (TEE).

      HYPOTHESIS A comprehensive strategy of TEE based aspirin treatment in AF patients eligible
      for VKA therapy is safe and feasible.

      OBJECTIVES

        1. To show that TEE based aspirin treatment is safe when compared with VKA therapy.

        2. To test the feasibility of TEE as a tool to detect all four echocardiographic features
           of high stroke risk.

      METHODS In this multi centre pilot study we will perform TEE in patients with AF who are
      eligible for VKA treatment. TTE will be used as pre-screening: if TTE shows left atrial
      abnormalities or aortic plaque, patients will be excluded from randomisation. TEE will be
      performed in all other patients to detect or exclude complex aorta plaques or signs of left
      atrial stasis. Three hundred patients who do not have these features on TTE will be randomly
      assigned to treatment with aspirin or VKA. Follow-up will be 1 year.

      EXPECTED RESULTS Application of a new echo-guided antithrombotic strategy as proposed herein
      is feasible and may help to reduce bleeding whilst stroke prevention is maintained. If the
      lower limit of the 95% confidence interval of the yearly incidence of the primary endpoint on
      aspirin remains below 4.4% then a large multi centre randomised controlled trial will be
      performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A composite of the following endpoints: ischemic stroke, systemic embolism, major bleeding, acute coronary syndrome, death.</measure>
    <time_frame>at least 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion of a technical adequate TTE/TEE on the four echocardiographic features of high stroke risk.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">227</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ascal 100mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coumarin derivates</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acenocoumarol or fenprocoumon</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transoesophageal echocardiography</intervention_name>
    <description>TEE</description>
    <arm_group_label>Aspirin</arm_group_label>
    <arm_group_label>Coumarin derivates</arm_group_label>
    <other_name>No other names</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented atrial fibrillation or atrial flutter, paroxysmal or permanent

          -  Conventional indication for VKA treatment

          -  Signed informed consent

        Exclusion Criteria:

          -  Planned electro cardioversion

          -  Very high risk of TE (previous ischemic stroke or systemic TE, symptoms of heart
             failure or left ventricular dysfunction, mitral valve stenosis, hypertrophic
             cardiomyopathy)

          -  Indication for VKA treatment other than atrial fibrillation (e.g. mechanic valve
             prosthesis)

          -  Atrial fibrillation secondary to reversible diseases (e.g. thyrotoxicosis)

          -  Contraindication for treatment with VKA, aspirin, or clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HJGM Crijns, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academisch Ziekenhuis Maastricht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Twenteborg</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum Heerlen</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Meppel</name>
      <address>
        <city>Meppel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCN</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viecuri</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>September 5, 2011</last_update_submitted>
  <last_update_submitted_qc>September 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Interuniversity Cardiology Institute of the Netherlands</investigator_affiliation>
    <investigator_full_name>NHT Dinh</investigator_full_name>
    <investigator_title>Drs.</investigator_title>
  </responsible_party>
  <keyword>Echocardiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

